STOCK TITAN

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's management team will engage in a fireside chat session scheduled for Monday, June 9 at 8:40 am ET in Miami, FL. Investors and interested parties can access the live webcast through BridgeBio's investor relations website, with a replay available for 30 days following the event.
BridgeBio Pharma (Nasdaq: BBIO), un'azienda biofarmaceutica specializzata nelle malattie genetiche, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità 2025 organizzata da Goldman Sachs. Il team dirigenziale della società parteciperà a una sessione di discussione informale prevista per lunedì 9 giugno alle 8:40 ET a Miami, FL. Investitori e interessati potranno seguire la diretta streaming tramite il sito web delle relazioni con gli investitori di BridgeBio, con una replica disponibile per 30 giorni dopo l'evento.
BridgeBio Pharma (Nasdaq: BBIO), una compañía biofarmacéutica especializada en enfermedades genéticas, anunció su participación en la 46ª Conferencia Global Anual de Salud 2025 de Goldman Sachs. El equipo directivo de la empresa participará en una charla informal programada para el lunes 9 de junio a las 8:40 am ET en Miami, FL. Los inversores y personas interesadas podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de BridgeBio, con una repetición disponible durante 30 días después del evento.
유전 질환을 전문으로 하는 생명공학 제약회사 BridgeBio Pharma(Nasdaq: BBIO)는 2025년 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사 경영진은 6월 9일 월요일 오전 8시 40분(동부시간) 마이애미, 플로리다에서 예정된 화상 대화 세션에 참여할 예정입니다. 투자자 및 관심 있는 분들은 BridgeBio 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며, 행사가 끝난 후 30일 동안 다시보기 서비스를 이용할 수 있습니다.
BridgeBio Pharma (Nasdaq : BBIO), une entreprise biopharmaceutique spécialisée dans les maladies génétiques, a annoncé sa participation à la 46e Conférence mondiale annuelle sur la santé 2025 de Goldman Sachs. L'équipe dirigeante de la société participera à une discussion informelle prévue le lundi 9 juin à 8h40 ET à Miami, FL. Les investisseurs et les personnes intéressées pourront accéder à la diffusion en direct via le site web des relations investisseurs de BridgeBio, avec une rediffusion disponible pendant 30 jours après l'événement.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen, das sich auf genetische Erkrankungen spezialisiert hat, gab seine Teilnahme an der 46. jährlichen globalen Gesundheitskonferenz 2025 von Goldman Sachs bekannt. Das Managementteam des Unternehmens wird an einer Fireside-Chat-Sitzung teilnehmen, die für Montag, den 9. Juni, um 8:40 Uhr ET in Miami, FL, geplant ist. Investoren und Interessierte können den Live-Webcast über die Investor-Relations-Website von BridgeBio verfolgen; eine Wiederholung ist 30 Tage nach der Veranstaltung verfügbar.
Positive
  • None.
Negative
  • None.

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET.

To access the live webcast of BridgeBio’s presentation during the fireside chat, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, VP Strategic Finance
ir@bridgebio.com


FAQ

When is BridgeBio (BBIO) presenting at the Goldman Sachs Healthcare Conference 2025?

BridgeBio is scheduled to present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025, at 8:40 am ET in Miami, FL.

How can I watch BridgeBio's (BBIO) presentation at the Goldman Sachs Healthcare Conference?

The presentation can be accessed through the live webcast on BridgeBio's investor relations website at http://investor.bridgebio.com under the Events & Presentations page.

How long will BridgeBio's (BBIO) Goldman Sachs Conference presentation replay be available?

The webcast replay will be available on BridgeBio's website for 30 days following the event.

What type of presentation will BridgeBio (BBIO) give at the Goldman Sachs Healthcare Conference?

BridgeBio's management team will participate in a fireside chat format presentation at the conference.
Bridgebio Pharma

NASDAQ:BBIO

BBIO Rankings

BBIO Latest News

BBIO Stock Data

6.29B
163.48M
5.41%
91.1%
11.65%
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO